vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and WATTS WATER TECHNOLOGIES INC (WTS). Click either name above to swap in a different company.
WATTS WATER TECHNOLOGIES INC is the larger business by last-quarter revenue ($625.1M vs $622.0M, roughly 1.0× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 13.4%, a 21.0% gap on every dollar of revenue. On growth, WATTS WATER TECHNOLOGIES INC posted the faster year-over-year revenue change (15.7% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
AERCO International, Inc. is a manufacturer and supplier of commercial condensing boilers, high efficiency water heating equipment and energy recovery systems in the HVAC/plumbing industry across a variety of markets including education, lodging, government, office buildings, healthcare, industrial and multifamily housing. In 1949, AERCO introduced the industry's first semi-instantaneous, tankless steam-to-water water heater. In 1988, AERCO introduced the first condensing and fully modulating...
RPRX vs WTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $625.1M |
| Net Profit | $214.2M | $83.7M |
| Gross Margin | — | 49.5% |
| Operating Margin | 62.4% | 18.2% |
| Net Margin | 34.4% | 13.4% |
| Revenue YoY | 4.8% | 15.7% |
| Net Profit YoY | 2.9% | 24.0% |
| EPS (diluted) | $0.49 | $2.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $625.1M | ||
| Q3 25 | $609.3M | $611.7M | ||
| Q2 25 | $578.7M | $643.7M | ||
| Q1 25 | $568.2M | $558.0M | ||
| Q4 24 | $593.6M | $540.4M | ||
| Q3 24 | $564.7M | $543.6M | ||
| Q2 24 | $537.3M | $597.3M | ||
| Q1 24 | $568.0M | $570.9M |
| Q4 25 | $214.2M | $83.7M | ||
| Q3 25 | $288.2M | $82.2M | ||
| Q2 25 | $30.2M | $100.9M | ||
| Q1 25 | $238.3M | $74.0M | ||
| Q4 24 | $208.2M | $67.5M | ||
| Q3 24 | $544.0M | $69.1M | ||
| Q2 24 | $102.0M | $82.0M | ||
| Q1 24 | $4.8M | $72.6M |
| Q4 25 | — | 49.5% | ||
| Q3 25 | — | 48.8% | ||
| Q2 25 | — | 50.6% | ||
| Q1 25 | — | 48.8% | ||
| Q4 24 | — | 46.7% | ||
| Q3 24 | — | 47.3% | ||
| Q2 24 | — | 47.7% | ||
| Q1 24 | — | 46.9% |
| Q4 25 | 62.4% | 18.2% | ||
| Q3 25 | 70.1% | 18.2% | ||
| Q2 25 | 36.3% | 21.0% | ||
| Q1 25 | 94.0% | 15.7% | ||
| Q4 24 | 60.9% | 16.5% | ||
| Q3 24 | — | 17.1% | ||
| Q2 24 | 50.2% | 18.7% | ||
| Q1 24 | -13.0% | 16.9% |
| Q4 25 | 34.4% | 13.4% | ||
| Q3 25 | 47.3% | 13.4% | ||
| Q2 25 | 5.2% | 15.7% | ||
| Q1 25 | 41.9% | 13.3% | ||
| Q4 24 | 35.1% | 12.5% | ||
| Q3 24 | 96.3% | 12.7% | ||
| Q2 24 | 19.0% | 13.7% | ||
| Q1 24 | 0.8% | 12.7% |
| Q4 25 | $0.49 | $2.50 | ||
| Q3 25 | $0.67 | $2.45 | ||
| Q2 25 | $0.07 | $3.01 | ||
| Q1 25 | $0.55 | $2.21 | ||
| Q4 24 | $0.46 | $2.02 | ||
| Q3 24 | $1.21 | $2.06 | ||
| Q2 24 | $0.23 | $2.44 | ||
| Q1 24 | $0.01 | $2.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $405.5M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $2.0B |
| Total Assets | $19.6B | $2.9B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $405.5M | ||
| Q3 25 | $938.9M | $457.7M | ||
| Q2 25 | $631.9M | $369.3M | ||
| Q1 25 | $1.1B | $336.8M | ||
| Q4 24 | $929.0M | $386.9M | ||
| Q3 24 | $950.1M | $303.9M | ||
| Q2 24 | $1.8B | $279.4M | ||
| Q1 24 | $843.0M | $237.1M |
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $2.0B | ||
| Q3 25 | $9.6B | $2.0B | ||
| Q2 25 | $9.5B | $1.9B | ||
| Q1 25 | $9.8B | $1.8B | ||
| Q4 24 | $10.3B | $1.7B | ||
| Q3 24 | $10.3B | $1.7B | ||
| Q2 24 | $9.8B | $1.6B | ||
| Q1 24 | $9.9B | $1.6B |
| Q4 25 | $19.6B | $2.9B | ||
| Q3 25 | $19.3B | $2.7B | ||
| Q2 25 | $18.3B | $2.6B | ||
| Q1 25 | $17.6B | $2.5B | ||
| Q4 24 | $18.2B | $2.4B | ||
| Q3 24 | $18.0B | $2.4B | ||
| Q2 24 | $17.7B | $2.4B | ||
| Q1 24 | $16.1B | $2.3B |
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $154.7M |
| Free Cash FlowOCF − Capex | — | $140.3M |
| FCF MarginFCF / Revenue | — | 22.4% |
| Capex IntensityCapex / Revenue | — | 2.3% |
| Cash ConversionOCF / Net Profit | 3.86× | 1.85× |
| TTM Free Cash FlowTrailing 4 quarters | — | $356.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $154.7M | ||
| Q3 25 | $702.6M | $122.4M | ||
| Q2 25 | $364.0M | $69.7M | ||
| Q1 25 | $596.1M | $55.2M | ||
| Q4 24 | $742.5M | $139.5M | ||
| Q3 24 | $703.6M | $90.7M | ||
| Q2 24 | $658.2M | $85.3M | ||
| Q1 24 | $664.6M | $45.6M |
| Q4 25 | — | $140.3M | ||
| Q3 25 | — | $110.9M | ||
| Q2 25 | — | $59.5M | ||
| Q1 25 | — | $45.6M | ||
| Q4 24 | — | $127.5M | ||
| Q3 24 | — | $84.3M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $35.5M |
| Q4 25 | — | 22.4% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | — | 9.2% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | 23.6% | ||
| Q3 24 | — | 15.5% | ||
| Q2 24 | — | 13.1% | ||
| Q1 24 | — | 6.2% |
| Q4 25 | — | 2.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 2.2% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
| Q4 25 | 3.86× | 1.85× | ||
| Q3 25 | 2.44× | 1.49× | ||
| Q2 25 | 12.06× | 0.69× | ||
| Q1 25 | 2.50× | 0.75× | ||
| Q4 24 | 3.57× | 2.07× | ||
| Q3 24 | 1.29× | 1.31× | ||
| Q2 24 | 6.45× | 1.04× | ||
| Q1 24 | 139.10× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
WTS
Segment breakdown not available.
